NCT04858204已完成不适用
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer: a French Observational Multicenter Study of 259 Patients (ABCT-IMMUNOBZH)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 259
- 试验地点
- 7
- 主要终点
- Nivolumab Objective response rate
研究概览
简要总结
Data regarding nivolumab as second line treatment in advanced non-small cell lung cancer (NSCLC) are based on selected populations and might not reflect daily practice. Investigators aimed at assessing efficacy and safety of nivolumab in a real-life setting and determining a subtype of NSCLC patients that are more likely to benefit from immunotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •advanced NSCLC (stage IIIB-IV)
- •failure of at least one line of chemotherapy.
- •age ≥18 years,
- •initiation of nivolumab between 01/09/2015 and 30/09/2016.
排除标准
- •nivolumab initiation after October 2016
- •prior involvement in an immunotherapy trial
- •refusal to participate.
结局指标
主要结局
Nivolumab Objective response rate
时间窗: through study completion, an average of 1 year
Objective response rate evaluated by RECIST 1.1
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
已完成
不适用
Real-world Data of Nivolumab in Pre-treated NSCLCNon Small Cell Lung CancerNCT04713462Hellenic Cooperative Oncology Group346
已完成
4 期
Study of Nivolumab for Advanced Cancers in IndiaNon-Small Cell Lung Cancer (NSCLC)Non-Small-Cell Lung CarcinomaNonsmall Cell Lung CancerKidney CancerKidney NeoplasmsRenal CancerRenal NeoplasmsNCT03444766Bristol-Myers Squibb100
已完成
不适用
Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior ChemotherapyNon-Small Cell Lung CancerNCT02910999Bristol-Myers Squibb868
撤回
2 期
Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung CancerRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung CancerNCT03121417Emory University
已完成
不适用
Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU ProgramNivolumabLong-term Adverse EffectsNon-small Cell Lung CancerNCT02933346Intergroupe Francophone de Cancerologie Thoracique907